Pharmacutical Daily
@PharmacDaily
Followers
2K
Following
22
Media
1K
Statuses
60K
Pharmaceutical News - Direct Information
Joined September 2015
Arecor Therapeutics brings more subjects Phase I trial of its insulin candidate https://t.co/TaUTgbg4iw via @PharmacDaily
pharmaceuticaldaily.com
Arecor Therapeutics has decided to increase the number of subjects within its ongoing Phase I clinical trial of ultra-rapid, ultra-concentrated insulin candidate AT278, in line with the update prov…
0
1
1
NIH Awards $14.4 Million to NDRI to Collaborate on the Somatic Mosaicism across Human Tissues (SMaHT) Network
pharmaceuticaldaily.com
PHILADELPHIA–(BUSINESS WIRE)–#BoardofDirectors–The National Disease Research Interchange (NDRI), in collaboration with the University of Maryland School of Medicine and Johns Hopk…
0
1
1
Global Royalty Rate Trends in Pharma and Biotech Dealmaking Analysis Report 2023: Technology Licensed, Royalty Rates, License Fees, Upfront and Milestone Payments – https://t.co/8vPVgQmo6R
pharmaceuticaldaily.com
DUBLIN–(BUSINESS WIRE)–The “Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023” report has been added to ResearchAndMarkets.com’s offering. The Glob…
0
0
0
AmbioPharm Provides an Update on South Carolina Headquarters Expansion
pharmaceuticaldaily.com
NORTH AUGUSTA, S.C.–(BUSINESS WIRE)–#CDMO–AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial pept…
0
0
0
Lauren Boyer of Underscore Named One of the 2023 PM360 ELITE 100
pharmaceuticaldaily.com
NEW YORK–(BUSINESS WIRE)–PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, has named Lauren …
0
0
0
PatientsLikeMe Shares Amyotrophic Lateral Sclerosis (ALS) Data to Expand PRO-ACT Database
pharmaceuticaldaily.com
Data from digital platform to support Massachusetts General Hospital’s efforts to advance clinical researchBOSTON–(BUSINESS WIRE)–PatientsLikeMe (PLM), the trusted digital platform that…
0
0
0
Deepcell Launches AI-Powered Single Cell Analysis Platform to Accelerate Cell Biology Discovery and Catalyze Field of Morpholomics
pharmaceuticaldaily.com
Benchtop REM-I Platform enables unprecedented insights into cell biology through scalable single cell imaging, high-dimensional analysis and cell sorting Company to present research at CYTO 2023 hi…
0
0
0
Alliance Pharma and Drug Development Solutions Are Now Resolian
pharmaceuticaldaily.com
MALVERN, Pa.–(BUSINESS WIRE)–Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Deve…
0
0
0
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
pharmaceuticaldaily.com
Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical FoodVANCOUVER, British Columbia–(BUSINESS WIRE)–Lobe Sciences Ltd.…
0
0
0
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
pharmaceuticaldaily.com
— First head-to-head randomized clinical trial (RCT) of DynamX Bioadaptor compared to Resolute Onyx DES shows statistically significant effectiveness in restoring vessel pulsatility, achieving sign…
0
0
0
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
pharmaceuticaldaily.com
– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and Other So…
0
0
0
Ribbon Biolabs Announces Presentation and Broad Participation at Upcoming SynBioBeta 2023 Conference
pharmaceuticaldaily.com
VIENNA–(BUSINESS WIRE)–Ribbon Biolabs, the DNA synthesis company, today announced its participation in the SynBioBeta 2023 conference, held from May 23 to May 25, 2023, in Oakland, CA. …
0
0
0
Bayer Receives U.S. FDA Fast Track Designation for asundexian Atrial Fibrillation Program
pharmaceuticaldaily.com
Not intended for UK Media The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries…
0
0
0
Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 – https://t.co/8vPVgQlQhj
pharmaceuticaldaily.com
DUBLIN–(BUSINESS WIRE)–The “Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023” report has been added to ResearchAndMarkets.com’s offering.…
0
0
0
Intrance Medical Systems Appoints Ashley Prange as Vice President of Business Development
pharmaceuticaldaily.com
— Company to strengthen focus on strategic partnerships to include ex-U.S. out-licensing activities and U.S. commercial collaborationsNEW YORK–(BUSINESS WIRE)–Intrance Medical Sys…
0
0
0
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
pharmaceuticaldaily.com
BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Kar…
0
0
1
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
pharmaceuticaldaily.com
– Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company’s commercial strategy and capabilities -WALTHAM, …
0
0
0
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer
pharmaceuticaldaily.com
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trialSAN DIEGO–(BUSINESS…
0
0
0
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
pharmaceuticaldaily.com
The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The investigator-…
0
0
0
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
pharmaceuticaldaily.com
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) tr…
0
0
0